Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Triferic’s ESA-Reduction Claim Draws FDA Skepticism Ahead Of ODAC Review

This article was originally published in The Pink Sheet Daily

Executive Summary

Rockwell’s iron replacement therapy could be hindered by absence of ESA-reduction claim even if drug makes it through FDA with more limited indication; agency will have to address its own discrepancies in briefing document data at the Nov. 6 Oncologic Drugs Advisory Committee.

You may also be interested in...



Rockwell Sees Opportunity For Triferic In Cost-Sensitive CKD Market

Rockwell Medical has filed an NDA for the iron replacement therapy, which will be positioned as an alternative to I.V. iron during dialysis and could limit the need for erythropoietin-stimulating agents.

Aduhelm’s Post-Marketing Studies: At Least One More Data Dump Likely Required By NIH

Pulling the controversial Alzheimer’s drug’s BLA should not exempt Biogen from fulfilling ClinicalTrials.gov reporting requirements for two key studies, even if the research gets terminated, former head of the NIH data repository tells the Pink Sheet.

CMS Expects Part D Plans To Go To Great Lengths Facilitating Participation In New Copay ‘Smoothing’ Option

The Medicare draft guidance seems designed to ensure seniors don’t miss out on the IRA benefit. 

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS076697

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel